Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Robert Busch, MD: Topline Results of EMPEROR-REDUCED
31 Jul 2020
In this episode we will be discussing reaction to topline results from the EMPEROR-REDUCED trial examining the use of empagliflozin for heart failure in patients with and without diabetes with endocrinologist Dr. Robert Busch. Announced on July 30, by Berringer Ingelheim and Lilly,topline results indicate use of empagliflozin was associated with a decrease in the composite endpoint of CV death and worsening heart failure. Scheduled to be presented at ESC 2020, the results will be presented 1 year after the results of DAPA-HF. Now, results of EMPEROR-REDUCED have a chance to firmly cement the notion that the benefit on heart failure proven in clinical trials with dapagliflzoin and potentially empaglfilziin is truly a class effect of SGLT2s.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
13:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
10:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
13:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana